Evotec AG has announced a second strategic alliance with Harvard University, this time to discover and develop biomarkers and treatments for kidney disease. This follows an earlier deal to develop diabetes therapies targeting beta cell regeneration. ---Subscribe to MedNous to access this article--- Finance, Grants, Deals Company News
